United States - English - NLM (National Library of Medicine)

dash pharmaceuticals llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium and misoprostol delayed-release tablets should not be taken by pregnant women. diclofenac sodium and misoprostol delayed-releas

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium and misoprostol delayed-release tablets should not be taken by pregnant women. diclofena

United States - English - NLM (National Library of Medicine)

eagle pharmaceuticals, inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), misoprostol (unii: 0e43v0bb57) (misoprostol - unii:0e43v0bb57) - diclofenac sodium 50 mg - carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing nsaid-induced gastric and duodenal ulcers and their complications. see warnings, gastrointestinal effects - risk of ulceration, bleeding and perforation for a list of factors that may increase the risk of nsaid-induced gastric and duodenal ulcers and their complications. see boxed contraindications and warnings related to misoprostol. diclofenac sodium and misoprostol delayed-release tablets should not be taken by pregnant women. diclofenac sodium and misoprostol delayed-releas

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 542.52 mg (equivalent: dicloxacillin sodium, qty 500 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide; patent blue v; quinoline yellow - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dicloxacillin sodium, quantity: 271.26 mg (equivalent: dicloxacillin, qty 250 mg) - capsule - excipient ingredients: silicon dioxide; magnesium stearate; gelatin; titanium dioxide - dicloxsig is indicated in the treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia. note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia. bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxsig should not be used in infections due to organisms susceptible to benzylpenicillin. important note: when it is judged necessary that the treatment be initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase resistant penicillin.

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - heparin sodium - solution for injection concentrate for solution for infusion - heparin sodium 1000 iu/ml - antithrombotic agents

Kenya - English - Pharmacy and Poisons Board

united pharma (k) limited p.o. box 77927-00622 - benzylpenicillin (as sodium) - injection - 50 vials each contains: benzylpenicillin (as… - other antibiotics for topical use

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

antibiotice s.a. - benzylpenicillin (benzylpenicillin sodium) - powder for solution for injection - 1000000 iu

Uganda - English - National Drug Authority

sino africa medicines and health ltd - benzylpenicillin sodium - parenteral ordinary dry vials - 1000000 i.u

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.